Clinical study of a new type of artificial liver support-Single-pass albumin diafiltration in treatment of liver failure
AIM: To study the curative effect of single-pass albumin diafiltration ( SPADF),a new type of artificial liver support system,in the treatment of liver failure patients. METHODS: Twenty-six patients with liver failure were enrolled and treated intermittently 34 times with SPADF. Parameters in the blood were detected and compared before and after treatment. RESULTS: There were remarkable improvements in clinical symptoms and physical signs,especially in hepatic encephalopathy. The prothrombin activity ( PTA) and cholinesterase ( CHE) increased significantly (P < 0. 05 ) and the serum blood urea nitrogen (BUN),serum creatinine (SCr),total bilirubin (TB),total bile acid (TBA),serum ammonia (NH3 ),interleukin-1 (IL-1 ),interleukin-6 (IL-6 ),alanine aminotransferase (ALT) and tumor necrosis factor-α (TNF-α ) decreased obviously (P < 0.05). Twelve patients were discharged from the hospital and 4 patients were bridged successfully to liver transplantation. The overall survival rate of SPADF treatment was 61%. CONCLUSION: Single-pass albumin diafiltration is a safe,simple,convenient and effective therapeutic method for liver failure patients,which merits further study and wide application.
albumin diafiltrationliver failureliver,artificial
NETL
NSTL
万方数据
维普
